Core Viewpoint - China Antibody-B (03681) has seen a significant stock price increase of over 15%, currently trading at 2.7 HKD, with a transaction volume of 6108.39 HKD, following the release of its interim performance announcement for the period ending June 30, 2025 [1] Financial Performance - The total other income and revenue for the reporting period is approximately 9.802 million RMB, representing a year-on-year increase of 126.95% [1] - Research and development costs amounted to 32.74 million RMB, with a reduction in losses by 40.8 million RMB, primarily due to decreased expenses related to the preparation for the BLA of Shuxili monoclonal antibody and reduced hiring costs [1] Clinical Development - The company has made significant progress in its clinical trial projects and pipeline development, particularly with its two core products, Shuxili monoclonal antibody and SM17 [1] - Shuxili monoclonal antibody has achieved breakthrough results in preclinical studies for the treatment of systemic lupus erythematosus (SLE), demonstrating unique advantages in regulating the autoimmune network and protecting against organ damage [1] - The product has shown a significant reduction in anti-double-stranded DNA (anti-dsDNA) antibody levels and has outperformed existing drugs in improving proteinuria and renal pathological damage associated with lupus nephritis (LN) [1]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 2024 年 7 月 16 日， 海军军医大学第二附属医院 （上海长征医院） 徐沪济 教授 联合 邦耀生物 、华东师范大学、浙江大学医学院第二 附属医院的研究人员，在 Cell 期刊发表论文 【1】 ，使用经过 CRISPR 基因编辑改造的现货通用型 CAR-T 细胞疗法来成功治疗了三名难治性自身免疫疾病患者。 徐沪济 教授因此入选了 Nature 评选的 2024 年度十大人物榜单 （Nature's 10） ， Nature 在对该榜单的报道中提到，清华大学 林欣 教授创立的 华夏英泰 正在 与 徐 沪济 团队合作开展通用型 T 细胞疗法治疗 系统性红斑狼疮 的人体试验。 2025 年 8 月 27 日，这项研究在 Nature Medicine 期刊正式发布 【2】 。论文题为： Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial （用于难治性系统性红斑狼疮的同种异体 CD19 靶向的 T 细胞：一项 1 期 ...

Core Insights - The National Medical Products Administration (NMPA) has accepted the market application for AstraZeneca's Avolimumab injection for the treatment of systemic lupus erythematosus (SLE) [1] Company Summary - Avolimumab is a first-in-class fully human monoclonal antibody that targets the type I interferon receptor 1 (IFNAR1), thereby blocking the activity of type I interferons [1] - The IFNAR1 receptor forms a heterodimer with IFNAR2, which is a key cytokine involved in regulating the inflammatory pathways of SLE [1] - Increased signaling through the type I interferon receptor is associated with higher disease activity and severity in SLE [1]